Preparation excellent in elution property and tableting property
Patent Information
- Application Number
- MYPI2026001229
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-29
- Filing Date
- 2024-09-26
- Publication Date
- 2025-03-29
AI Technical Summary
Existing oral solid formulations of the compound 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide face challenges with tableting problems such as sticking and capping, and require formulations with good elution and storage stability across a wide range of doses.
The use of higher-than-normal ratios of hydroxypropylcellulose as a binder and sodium stearyl fumarate as a lubricant in the oral solid formulation, which allows for improved fluidity and prevents tableting issues while maintaining good elution properties and storage stability.
This approach results in oral solid formulations that effectively suppress tableting problems, maintain excellent elution and storage stability, and provide a wide range of dosing options from low to high doses.
Abstract
Description
Formulation with excellent dissolution and tableting properties
[0001] The present disclosure relates to an oral solid formulation which contains, as an active ingredient, 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide (hereinafter also referred to as "the present compound") or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof (hereinafter, the present compound through the solvate are also referred to as the "drug," the "drug," or the "drug of the present disclosure"), and which has good dissolution properties and storage stability and, when produced as a tablet, is suppressed from causing tableting problems.
[0002] Obtaining information regarding dose and response is important in clinical development planning. According to Non-Patent Document 1, the purpose of dose-response analysis is to collect necessary information at each stage throughout non-clinical and clinical development, and to utilize this useful information in subsequent clinical trials and post-marketing use. That is, it is important to understand the relationship between dose, blood concentration, and clinical response (efficacy and safety) and identify the appropriate starting dose for a group or individual patient, the best way to adjust the dose to suit the needs of a specific patient, and the dose at which further benefit is not expected or at which an increase in the dose is likely to cause unacceptable side effects, and use these to advance to the next stage. Furthermore, since the dose may be changed during clinical development, it is preferable to obtain oral solid dosage forms that cover a wide dose range, from low to high, in order to obtain such information.
[0003] When a solid preparation is orally administered, in order to exert its effects, the dissolved drug must reach the absorption site after going through the processes of disintegration, dispersion, and dissolution. Since this process has a significant effect on drug absorption, it is desirable to design the preparation so that it can maintain stable and good dissolution in order to exert and maintain its pharmacological effect.
[0004] Patent Document 1 discloses a formulation of the present compound, but does not disclose any examples showing specific ingredients, formulations, or manufacturing methods.
[0005] WO2020 / 045334
[0006] Guidelines for Dose-Response Studies for the Approval of New Drugs (ICH E4)
[0007] An object of the present disclosure is to provide an oral solid formulation of the present drug that has good dissolution properties and storage stability, and further, when produced as a tablet, to provide an oral solid formulation that suppresses tableting problems.
[0008] It has been found that when this drug is formulated into an oral solid dosage form, tableting problems occur during the tablet production process (i.e., the tableting process), such as adhesion of the drug-containing composition to the punch surface (so-called "sticking") and surface peeling (so-called "capping"). Generally, the incorporation of a binder and a lubricant tends to improve tableting problems during the tableting process. However, it is also known that increasing the amount of binder and lubricant beyond the appropriate amount can delay the dissolution rate of the compound and reduce the tablet moldability (reduced hardness). However, after extensive research, the present inventors surprisingly found that using binder and lubricant in amounts greater than the usual formulation ratios did not result in problems such as delayed dissolution or reduced hardness, and could improve fluidity and eliminate tableting problems.
[0009] As a result of intensive research, the present inventors have found that it is possible to provide an oral solid preparation with good dissolution properties and storage stability by incorporating a high content of both a lubricant and a binder in amounts greater than those normally used. Specifically, they have found that even when tablets are produced by incorporating a high content of hydroxypropyl cellulose as a binder and sodium stearyl fumarate as a lubricant, no delay in dissolution or reduction in hardness occurs, tableting problems are suppressed, and good dissolution properties are maintained while excellent storage stability is obtained, which has led to the completion of the present disclosure.
[0010] That is, the present disclosure provides the following:
[0011] [Item 1] An oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.0 to 6.0% by weight of a binder based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of a lubricant based on 100% by weight of the formulation.
[0012] [Item 2] The oral solid formulation according to Item 1, wherein the content of the binder is 5.0 to 6.0% by weight based on 100% by weight of the formulation.
[0013] [Item 3] The oral solid formulation according to Item 1 or 2, wherein the binder is a water-soluble polymer binder.
[0014] [Item 4] The oral solid formulation according to Item 3, wherein the water-soluble polymer binder is hydroxypropyl cellulose or polyvinyl alcohol.
[0015] [Item 5] The oral solid formulation according to Item 3, wherein the water-soluble polymer binder is hydroxypropyl cellulose.
[0016] [Item 6] The oral solid formulation according to any one of Items 1 to 5, wherein the content of the lubricant is 2.0 to 6.0% by weight based on 100% by weight of the formulation.
[0017] [Item 7] The oral solid formulation according to any one of Items 1 to 5, wherein the content of the lubricant is 4.0 to 6.0% by weight based on 100% by weight of the formulation.
[0018] [Item 8] The oral solid formulation according to Items 1 to 7, wherein the lubricant is sodium stearyl fumarate.
[0019] [Item 9] The oral solid formulation according to any one of Items 1 to 8, further comprising an excipient.
[0020] [Item 10] The oral solid formulation according to Item 9, wherein the excipient is a hydrophilic excipient.
[0021] [Item 11] The oral solid formulation according to Item 10, wherein the hydrophilic excipient is one or a mixture of two or more selected from the group consisting of sugar alcohols, pregelatinized starches, lactose hydrate, and crystalline cellulose.
[0022] [Item 12] The oral solid formulation according to Item 10, wherein the hydrophilic excipient is one or a mixture of two or more selected from sugar alcohols, pregelatinized starches, and crystalline cellulose.
[0023] [Item 13] The oral solid formulation according to Item 10, wherein the hydrophilic excipient is one or a mixture of two or more selected from the group consisting of sugar alcohols and pregelatinized starches.
[0024] [Item 14] The oral solid formulation according to Item 10, wherein the hydrophilic excipient is a mixture of sugar alcohol and pregelatinized starches.
[0025] [Item 15] The oral solid formulation according to any one of Items 11 to 14, wherein the pregelatinized starch is a partially pregelatinized starch.
[0026] [Item 16] The oral solid formulation according to any one of Items 11 to 15, wherein the sugar alcohol is D-mannitol.
[0027] [Item 17] The oral solid formulation according to any one of Items 1 to 16, further comprising a disintegrant.
[0028] [Item 18] The oral solid formulation according to Item 17, wherein the content of the disintegrant is 0.5 to 50.0% by weight based on 100% by weight of the formulation.
[0029] [Item 19] The oral solid formulation according to Item 17, wherein the content of the disintegrant is 0.5 to 30.0% by weight relative to 100% by weight of the formulation.
[0030] [Item 20] The oral solid formulation according to Item 17, wherein the content of the disintegrant is 0.5 to 20.0% by weight based on 100% by weight of the formulation.
[0031] [Item 21] The oral solid formulation according to any one of Items 17 to 20, wherein the disintegrant is one or a mixture of two or more selected from croscarmellose sodium, sodium starch glycolate, and crospovidone.
[0032] [Item 22] The oral solid formulation according to any one of Items 17 to 20, wherein the disintegrant is one or a mixture of two or more selected from croscarmellose sodium and sodium starch glycolate.
[0033] [Item 23] The oral solid formulation according to any one of Items 17 to 20, wherein the disintegrant is croscarmellose sodium.
[0034] [Item 24] The oral solid formulation according to any one of Items 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is 0.5 to 70% by weight, based on 100% by weight of the formulation.
[0035] [Item 25] The oral solid formulation according to any one of Items 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is 10 to 50% by weight, based on 100% by weight of the formulation.
[0036] [Item 26] The oral solid formulation according to any one of Items 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is 15 to 40% by weight, based on 100% by weight of the formulation.
[0037] [Item 27] The oral solid formulation according to any one of Items 1 to 23, wherein the content of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is 15 to 38% by weight, based on 100% by weight of the formulation.
[0038] [Item 28] The oral solid formulation according to any one of Items 1 to 23, wherein the content of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is 20 to 38% by weight, based on 100% by weight of the formulation.
[0039] [Item 29] The oral solid formulation according to any one of Items 1 to 28, which is produced using a fluidized bed granulation method.
[0040] [Item 30] The oral solid formulation according to any one of Items 1 to 29, which is film-coated with a coating agent.
[0041] [Item 31] The oral solid formulation according to any one of Items 1 to 30, for treating and / or preventing a tumor.
[0042] The oral solid preparation of the present disclosure can provide an oral solid preparation with good dissolution properties and storage stability by incorporating binders and lubricants in amounts higher than those usually used. Furthermore, the use of high amounts of binders and lubricants can suppress tableting problems and provide tablets that maintain good dissolution properties and have excellent storage stability.
[0043] The present disclosure will be described in more detail below. The embodiments provided below are provided for a better understanding of the present disclosure, and the scope of the present disclosure is not limited to the following descriptions. In addition, the following embodiments can be used alone or in combination.
[0044] In the present disclosure, the term "average particle size" refers to the cumulative 50% particle size D50 of powder particles measured on a volume basis using a laser diffraction particle size analyzer (e.g., a Particle Viewer manufactured by Powrex Corporation, a SALD-3000J manufactured by Shimadzu Corporation, or a HELOS & RODOS manufactured by Sympatec).
[0045] In the present disclosure, "tabletting problems" refers to the phenomenon in which the compound adheres to the surface of the punch during the tablet production process (i.e., the tableting process) (sticking), the phenomenon in which the surface peels off (capping), and the phenomenon in which friction occurs between the powder being tableted and the metal adhesion surface, causing scratches on the side of the tablet (die friction).
[0046] In the present disclosure, unless otherwise specified, the term "content" refers to the blend amount or content (wt / wt) when the total amount of the formulation is taken as 100% by weight. Note that "wt%" can also be expressed as "wt%."
[0047] In the present disclosure, "excellent storage stability" refers to a formulation characteristic in which the increase in the amount of related substances is small in a purity test of a storage stability test, and good dissolution properties are maintained in a dissolution test after storage.
[0048] "Storage" refers to leaving, storing, or preserving a manufactured formulation in an appropriate container. During storage, the container may be sealed or open, and may or may not be protected from light. Examples of storage include room temperature storage, room temperature storage, cold place storage, refrigerated storage, and frozen storage. Storage temperatures include, but are not limited to, standard temperature: 20°C, room temperature: 15-25°C, room temperature: 1-30°C, tepid temperature: 30-40°C, cold place: 1-15°C, refrigerated: 2-6°C, and frozen: approximately -20°C to -18°C. The relative humidity (% RH) during storage may be anywhere from 0 to 100% RH, with 40 to 60% RH being preferred, but not limited to these. Storage periods include, but are not limited to, several hours, several days, several weeks, several months, or several years. The storage parameters can be appropriately selected depending on the properties of the formulation and the storage conditions. "Storage stability testing" is a stability test to confirm whether the quality of a manufactured formulation is maintained, and is conducted using storage conditions that accelerate chemical or physical changes in the formulation. The test results can be used to evaluate the chemical effects of long-term storage under the specified storage method. At the same time, they can also be used to evaluate the effects of short-term deviations from the storage method that may occur during transportation. Depending on the temperature / relative humidity, tests include long-term tests (e.g., 25°C / 60% RH), accelerated tests (e.g., 40°C / 75% RH), and stress tests (e.g., 50°C / 85% RH). The accelerated test or stress test herein is performed by setting the conditions of a thermo-hygrostat to a higher temperature / higher relative humidity (e.g., 40°C / 75% RH or 50°C / 85% RH, respectively), placing the prepared solid dosage form in an appropriate container (e.g., an HDPE bottle (material: high density polyethylene (HDPE) or an amber screw-cap test tube (material: glass)) and storing it in an opened or closed state in the thermo-hygrostat for a certain storage period (e.g., 1, 3, or 6 months, or 2 or 4 weeks, respectively). In order to provide patients with a high-quality dosage form, it is necessary to keep the amount of related substances in the storage stability test below a specified amount. The specified amount of related substances is generally a total related substance amount of 3.0% or less.
[0049] In the present disclosure, "good dissolution" means, for example, that when a dissolution test of a formulation is conducted according to the paddle method of the Japanese Pharmacopoeia, 18th Edition, under the following dissolution test conditions, a dissolution rate of 80% or more, preferably 85% or more, is shown at 15 minutes. Another aspect of "good dissolution" is that a dissolution rate of 70% or more, preferably 80% or more, more preferably 85% or more, is shown at 10 minutes. Yet another aspect of "good dissolution" is that a dissolution rate of 80% or more, preferably 85% or more, is shown at 5 minutes. Test solution: 0.1 mol / L hydrochloric acid test solution Paddle rotation speed: 50 rpm Test solution: 900 mL Test solution temperature: 37±0.5°C
[0050] [1] Oral solid preparations "Oral solid preparations" refer to solid preparations of a certain shape that are administered orally. Solid preparations include those formulated into dosage forms such as tablets, capsules, granules, fine granules, pills, and powders.
[0051] The oral solid formulation of the present disclosure particularly refers to those formulated into tablets, capsules, granules, or fine granules. Preferred examples of oral solid formulations include tablets or capsules. More preferred examples of oral solid formulations include tablets. Oral solid formulations (e.g., tablets) of the present disclosure can be film-coated with a coating agent for the purpose of facilitating administration or preventing decomposition of the active ingredient. In this case, the oral solid formulation of the present disclosure can be said to be a film-coated tablet. Film-coated tablets are typically tablets formulated by applying a film coating to a plain tablet with an appropriate coating agent such as a polymer compound.
[0052] The oral solid formulation of the present disclosure comprises (1) a drug, (2) a binder, (3) a lubricant, and may further comprise, as necessary, (4) an excipient, (5) a disintegrant, and optionally other (6) additives to the extent that they do not affect the formulation properties of the present disclosure. In the case of tablets, forms such as plain tablets, film-coated tablets (sometimes referred to herein as FC tablets) in which a film coating is applied to the surface of a plain tablet, and sugar-coated tablets in which a sugar coating is applied to the surface of a plain tablet are included, and plain tablets or film-coated tablets are preferred.
[0053] (1) Drug In the present disclosure, the term "drug" refers to the active ingredient of the present disclosure, 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide (the present compound) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and the present compound has the following structure: In addition, the term "hydrate or solvate thereof" in "the present compound or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof" refers to a hydrate or solvate of the present compound, and a hydrate or solvate of a pharmaceutically acceptable salt of the present compound.
[0054] In the present disclosure, "pharmaceutically acceptable salts" include, but are not limited to, hydrochloride, citrate, fumarate, maleate, phosphate, succinate, sulfate, tartrate, besylate, bromate, and the like.
[0055] The term "tartrate salt of the present compound" refers to 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide 1L(+)-tartrate salt. In the present disclosure, "hydrate" refers to a solid state in which a certain ratio of water molecules is contained in the molecules of the present compound, and "solvate" refers to a state in which the water molecules are organic solvent molecules. The organic solvent capable of forming the solvate in the present disclosure can be appropriately selected depending on the type and properties of the substance, and examples include common solvents such as alcohols such as ethanol and propanol, acetone, and ethyl acetate. The number of solvent molecules in the hydrate and solvate can be appropriately selected depending on the stability of the solvate, and the like.
[0056] The content of the drug of the present disclosure is typically 0.1 to 96% by weight, preferably 0.5 to 70% by weight, more preferably 5 to 60% by weight, 5 to 50% by weight, 10 to 60% by weight, 10 to 50% by weight, 15 to 60% by weight, 15 to 50% by weight, 10 to 40% by weight, 15 to 40% by weight, 20 to 40% by weight, 20 to 38% by weight, 15 to 38% by weight, 15 to 36% by weight, 20 to 36% by weight, and even more preferably 20 to 30% by weight.
[0057] When preparing a drug formulation, the drug may be pulverized to a desired particle size, if necessary. The average particle size of the drug is usually 0.1 to 100 μm, preferably 0.1 to 80 μm, more preferably 0.1 to 50 μm, and even more preferably 1 to 20 μm. The average particle size of the drug may be within the above range as a raw material, and may vary during the manufacturing process, etc.
[0058] (2) Binders: A "binder" refers to a component used to impart binding strength to powders and create and maintain the shape of the formulation. In the present disclosure, a water-soluble polymer binder is preferred. Examples of "water-soluble polymer binders" include, but are not limited to, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, polyethylene glycol, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, vinyl acetate-vinylpyrrolidone copolymer, polyvinyl alcohol-polyethylene glycol graft copolymer, pregelatinized starches, dextrin, dextran, pullulan, alginic acid, gelatin, and pectin. More preferred examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, and polyvinyl alcohol, and even more preferred examples include hydroxypropylcellulose. The water-soluble polymer binder may be one of the above or two or more of them may be used simultaneously. Hydroxypropylcellulose, a typical binder, is generally used at a concentration of 2-3%.
[0059] The use of hydroxypropyl cellulose as a water-soluble polymer binder allows for successful preparation of drug-containing granules (i.e., granulation) in formulation, and also allows for the production of formulations that are easy to handle and have good disintegration properties.
[0060] The viscosity of the hydroxypropyl cellulose is not particularly limited, but when made into a 2% aqueous solution at 20° C., it has a viscosity of 2 to 400 mPa·s, and preferably 2 to 10 mPa·s.
[0061] The binder content is typically 4.0 to 20% by weight, preferably 4.0 to 10% by weight, more preferably 4.0 to 6.0% by weight, 4.5 to 6.0% by weight, 5.0 to 6.0% by weight, 5.5 to 6.0% by weight, 4.0 to 5.5% by weight, 4.5 to 5.5% by weight, 5.0 to 5.5% by weight, 4.0 to 5.0% by weight, 4.5 to 5.0% by weight, and even more preferably 5.0 to 5.5% by weight and 5.0 to 6.0% by weight. The binder of the present disclosure can be dissolved in a solvent such as water and granulated while being sprayed. Furthermore, the binder can be charged together with other ingredients and granulated while being sprayed with a solvent such as water.
[0062] (3) Lubricants. A "lubricant" refers to a component added during the manufacturing process of capsules or tablets to improve powder fluidity, packing properties, and prevent adhesion during capsule filling or tablet compression. In the case of tablets, the lubricant may be mixed with other components before tableting or sprayed onto punches and dies during tableting. Examples of lubricants include, but are not limited to, magnesium stearate, sodium stearyl fumarate, talc, polyethylene glycol, silica, and hydrogenated vegetable oil. More preferred examples include magnesium stearate and sodium stearyl fumarate, and even more preferred examples include sodium stearyl fumarate. The lubricant may be one of the above or two or more of them at the same time. The use of sodium stearyl fumarate as a lubricant can suppress tableting problems during tableting and can produce formulations with excellent handleability and disintegration properties. A lubricant is generally added at 1% or less, and at most up to about 2%. A commonly used lubricant is magnesium stearate. The content of the lubricant is usually 0.1 to 20% by weight, preferably 2.0 to 10% by weight, more preferably 4.0 to 10% by weight, 5.0 to 10% by weight, 2.0 to 6.0% by weight, 2.5 to 6.0% by weight, 3.0 to 6.0% by weight, 3.5 to 6.0% by weight, 4.5 to 6.0% by weight, 5.0 to 6.0% by weight, and even more preferably 4.0 to 6.0% by weight, per 100% by weight of the preparation.
[0063] (4) Excipients An “excipient” is an ingredient that is added to form a dosage form when the active ingredient alone does not provide sufficient “bulk” to give the dosage form, to increase the dosage, or to dilute the dosage form to make it easier to handle. In addition to simply increasing the dosage, excipients also have the functions of improving the mixability of powders, improving the granulation properties when creating particles in granules, improving the filling properties, adhesion, and fluidity of tablets when tableting, and improving the filling properties of capsules.
[0064] Examples of "excipients" include hydrophilic excipients and non-hydrophilic excipients, preferably hydrophilic excipients. Hydrophilic excipients commonly used in formulations can be used as hydrophilic excipients, and preferred examples include sugar, crystalline cellulose, or sugar alcohols. The type of sugar or sugar alcohol used here is not particularly limited, and examples include pregelatinized starches, D-mannitol, erythritol, xylitol, maltitol, sorbitol, lactose, sucrose, and toruhalose. Preferred examples include D-mannitol, erythritol, lactose, and toruhalose. More preferred examples include pregelatinized starches, D-mannitol, and lactose. Most preferred examples include pregelatinized starches and D-mannitol. The hydrophilic excipient may be one selected from the above or a combination of two or more thereof.
[0065] The content of the excipient is usually 0.1 to 90% by weight, preferably 10 to 90% by weight, more preferably 30 to 80% by weight, and even more preferably 40 to 70% by weight, per 100% by weight of the preparation.
[0066] The content of D-mannitol is usually 0.1 to 90% by weight, preferably 1 to 80% by weight, and more preferably 30 to 60% by weight, based on 100% by weight of the preparation.
[0067] Specific examples of "gelatinized starches" include "gelatinized starch" or "partly pregelatinized starch" in the Pharmaceutical Excipients Standards, as well as "pregelatinized starch" in USP / NF and "starch, pregelatinized" in Ph. Eur. A preferred example of "gelatinized starches" is "partially pregelatinized starch." Specific examples of commercially available pregelatinized starches or partially pregelatinized starches include PC-10 (trade name, sold by Asahi Kasei Corporation), SWELSTAR (trade name, sold by Asahi Kasei Corporation), Starch 1500 and Starch 1500G (trade name, sold by Colorcon), or LYCATAB C (trade name, sold by Rockete), but are not limited thereto. Any pregelatinized starch or partially pregelatinized starch may be used as long as its components are pregelatinized starch or partially pregelatinized starch and its purity and other specifications satisfy the standards of those skilled in the art. Examples of raw materials for pregelatinized starches include various starches such as corn starch, potato starch, wheat starch, rice starch, and tapioca starch.
[0068] The content of pregelatinized starches is usually 0.1 to 50% by weight, preferably 1 to 40% by weight, and more preferably 10 to 30% by weight, per 100% by weight of the preparation.
[0069] (5) Disintegrants "Disintegrants" refer to components added to disintegrate and disperse solid preparations such as tablets or granules into particles. Examples of disintegrants include, but are not limited to, corn starch, croscarmellose sodium, sodium starch glycolate (or sodium carboxymethyl starch), low-substituted hydroxypropyl cellulose, carmellose, carmellose calcium, carboxymethylethyl cellulose, and crospovidone. Preferred examples include croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose, carmellose, carmellose calcium, and crospovidone. More preferred examples include croscarmellose sodium, sodium starch glycolate, and crospovidone. An even more preferred example is croscarmellose sodium. The disintegrant may be one selected from the above or a combination of two or more thereof.
[0070] The content of the disintegrant is usually 0.1 to 50.0% by weight, preferably 0.5 to 50.0% by weight, 0.5 to 30.0% by weight, more preferably 0.5 to 20% by weight, 0.5 to 30.0% by weight, 1.0 to 30.0% by weight, 1.0 to 20.0% by weight, and even more preferably 0.5 to 20.0% by weight, 2.0 to 10.0% by weight, 1.0 to 10.0% by weight, and 2.0 to 5.0% by weight, per 100% by weight of the preparation.
[0071] (6) Additives "Additives" refers to substances other than the active ingredients contained in the formulation that are used for purposes such as enhancing the usefulness of the active ingredients and the formulation, facilitating formulation, stabilizing quality, or improving usability.
[0072] Non-toxic and inactive additives commonly used in the pharmaceutical field can be added to the formulations of the present disclosure, as needed, as long as they do not affect the activity of the drug of the present disclosure. These additives include those commonly used in oral formulations that do not affect the therapeutic effect of the drug of the present disclosure. Examples of additives include, but are not limited to, stabilizers, flavoring agents, sweeteners, odorants, fragrances, antioxidants, antistatic agents, fluidizing agents, colorants, plasticizers, anti-agglomerating agents, and glossing agents. The content of the additives can be set at any desired level, but is typically 0.001 to 10 wt%, preferably 0.005 to 10 wt%, and more preferably 0.01 to 5 wt%, per 100 wt% of the formulation. Another preferred embodiment is an additive-free formulation.
[0073] A "coating agent" is a component used to coat the surface of a formulation, and is used to prevent contact with water, air, or light, mask odors or bitterness, impart pharmaceutical properties such as sustained release or enteric properties, or enhance the product's commercial value by improving its appearance. Examples of coating agents include, but are not limited to, combinations of a base material such as hypromellose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol graft copolymer, methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, aminoalkyl methacrylate copolymer RS, or ethyl acrylate-methyl methacrylate copolymer with a plasticizer such as polyethylene glycol, propylene glycol, triacetin, triethyl citrate, glycerin, or glycerin fatty acid ester. Additives such as titanium oxide, iron oxide, talc, and colorants can also be added. Mixtures of these additives may also be used, such as OPADRY.
[0074] "Coloring agent" refers to an ingredient used to identify capsules or tablets, to shield the contained pharmaceuticals from light, or to add commercial value. Coloring agents are not particularly limited, but examples include tar dyes, lake dyes, yellow ferric oxide, ferric oxide, and titanium oxide. Furthermore, after film coating, carnauba wax, talc, and the like can also be added as glossing agents.
[0075] The oral formulation of the present disclosure can be prepared in the desired dosage form according to conventional methods, although the preparation method varies depending on the desired dosage form. (1) Preparation of an aqueous solution of a binder: Dissolve the binder in purified water. The amount of the binder is selected, for example, from the range of 1 to 20% by weight, preferably from the range of 2 to 8% by weight, relative to the amount of purified water.
[0076] (2) Preparation of drug-containing granules of the present disclosure: The drug, water-soluble excipient, and disintegrant of the present disclosure are charged into a granulator, and the binder prepared in step (1) above is sprayed onto the granulator to granulate. Alternatively, a solvent such as water can be sprayed onto the granulator to granulate the drug, water-soluble excipient, disintegrant, and binder of the present disclosure. Granulation equipment includes, but is not limited to, fluid bed granulation, high-share granulation, roto-fluid bed granulation, and twin-screw granulation.
[0077] (3) Drying of Granulated Product: The granulated product is dried under reduced pressure or normal pressure so that the loss on drying measured with an infrared moisture meter is, for example, 4% by weight or less, preferably 2% by weight or less.
[0078] (4) Blending of lubricant: A lubricant is added to the granules dried in (3) above and mixed. For mixing, a mixer classified as a diffusion mixer (tumble) is used. Specific examples include a tumble blender, V blender, double cone, bin tumbler, etc., but are not limited to these.
[0079] (5) Tableting: The mixture is compressed to prepare tablets. Examples of the tableting device include a tablet press, etc. The tableting pressure is set by selecting the tablet hardness from a range of, for example, 20 to 250 N.
[0080] (6) Applying film coating if desired: The above tablets may be film-coated as needed. Examples of coating equipment include equipment classified as a coating pan. A preferred example is an equipment classified as a perforated coating system.
[0081] (7) Drying: The tablets obtained as described above are dried under reduced pressure or normal pressure so that the loss on drying measured with an infrared moisture meter is, for example, 4% by weight or less, preferably 2% by weight or less.
[0082] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.0 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0083] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 5.0 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0084] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.5 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0085] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.0 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0086] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.5 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0087] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 5.0 to 5.5% by weight of a binder, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0088] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 5.0 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0089] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 5.0 to 5.5% by weight of a binder, based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0090] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.5 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 2.0 to 6.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0091] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.5 to 6.0% by weight of a binder, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0092] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 5.0 to 5.5% by weight of a binder, based on 100% by weight of the formulation; and (3) 2.0 to 6.0% by weight of a lubricant, based on 100% by weight of the formulation; and optionally further comprising (4) an excipient, (5) a disintegrant, and / or (6) an additive, as needed.
[0093] In one embodiment of the present disclosure, there is provided an oral solid formulation comprising: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 5.0 to 6.0% by weight of hydroxypropyl cellulose relative to 100% by weight of the formulation; (3) 4.0 to 6.0% by weight of sodium stearyl fumarate relative to 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol; and (5) croscarmellose sodium; and optionally further comprising (6) an additive.
[0094] In one embodiment of the present disclosure, the formulation comprises: (1) 15 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 5.0 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0095] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 5.0 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0096] In one embodiment of the present disclosure, the formulation comprises: (1) 15 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0097] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.0 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0098] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.0 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0099] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0100] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0101] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 2.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0102] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0103] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 5.0 to 5.5% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0104] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 5.0 to 5.5% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0105] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 5.0 to 5.5% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 2.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol; and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0106] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 38% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 5.0 to 5.5% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; and (4) a mixture of partially pregelatinized starch and D-mannitol, based on 100% by weight of the formulation. (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0107] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 30% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 2.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0108] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 30% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 10.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0109] In one embodiment of the present disclosure, the formulation comprises: (1) 20 to 30% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 4.5 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol, and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0110] In one embodiment of the present disclosure, (1) 20 to 30% by weight of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, based on 100% by weight of the formulation; (2) 5.0 to 6.0% by weight of hydroxypropyl cellulose, based on 100% by weight of the formulation; and (3) 4.0 to 6.0% by weight of sodium stearyl fumarate, based on 100% by weight of the formulation; (4) a mixture of partially pregelatinized starch and D-mannitol; and (5) An oral solid formulation is provided which contains 0.5 to 20.0% by weight of croscarmellose sodium relative to 100% by weight of the formulation, and may further contain (6) an additive, if necessary.
[0111] [2] Pharmaceutical Use of Oral Solid Preparations The drug of the present disclosure exhibits anticancer activity by inhibiting the binding of menin to MLL (mixed lineage leukemia) fusion proteins formed by the fusion of AF4, AF9, and other typical fusion partner genes that cause MLL leukemia, and is therefore effective as an antitumor agent. Therefore, the present disclosure relates to a pharmaceutical composition, therapeutic agent, and / or preventive agent for treating cancer, preferably an oral solid preparation, containing the drug of the present disclosure.
[0112] In the present disclosure, "prevention" refers to the act of administering a drug of the present disclosure, which is an active ingredient, to a healthy person who has not developed a disease or is in good health at the time of administration, and a "prophylactic agent" is administered to such a healthy person, for example, with the purpose of preventing the onset of a disease, and is expected to be particularly appropriate for people who have previously had symptoms of a disease or who are considered to be at increased risk of developing a disease. "Treatment" refers to the act of administering a drug of the present disclosure, which is an active ingredient, to a person (patient) who has been diagnosed by a physician as having developed a disease, and a "therapeutic agent" is administered to such a patient, for example, with the purpose of alleviating the disease or symptoms, preventing the disease or symptoms from worsening, or restoring the patient to a state before the onset of the disease. Furthermore, even if the purpose of administration is to prevent the disease or symptoms from worsening, it is still a therapeutic act if the patient is administered to a patient.
[0113] "Cancer" and "tumor" are synonymous in the present disclosure and both refer to malignant tumors, including carcinomas, sarcomas, and hematological malignancies. Specific examples of "cancer" or "tumor" include acute leukemia (including MLL acute leukemia, MLL partial tandem duplication acute leukemia, NPM-mutated acute leukemia, MOZ acute leukemia, NUP98 acute leukemia, and CALM acute leukemia), chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, polycythemia vera, malignant lymphoma (including B-cell lymphoma), myeloma (including multiple myeloma), brain tumors, head and neck cancer, esophageal cancer, thyroid cancer, Examples of tumors include small cell lung cancer, non-small cell lung cancer, breast cancer, gastric cancer, gallbladder / bile duct cancer, liver cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, rectal cancer, anal cancer, choriothelial carcinoma, uterine cancer, cervical cancer, ovarian cancer, bladder cancer, urothelial cancer, kidney cancer, renal cell carcinoma, prostate cancer, testicular tumor, testicular germ cell tumor, ovarian germ cell tumor, Wilms' tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, chondrosarcoma, soft tissue sarcoma, and skin cancer. The above tumors may also be accompanied by elevated expression or mutation of specific genes. Examples of tumors accompanied by elevated gene expression include tumors accompanied by high expression of the HOXa gene group and tumors accompanied by high expression of the MEIS gene group. Examples of tumors accompanied by gene mutations include tumors accompanied by p53 gain-of-function mutations.
[0114] The drugs of the present disclosure can be used in combination with a "concomitant drug" to enhance their effects. Examples of the "concomitant drug" include antitumor alkylating agents, antitumor antimetabolites, antitumor antibiotics, plant-derived antitumor agents, antitumor platinum coordination compounds, antitumor camptothecin derivatives, antitumor tyrosine kinase inhibitors, antitumor serine-threonine kinase inhibitors, antitumor phospholipid kinase inhibitors, antitumor monoclonal antibodies, interferons, biological response modifiers, hormone preparations, immune checkpoint inhibitors, epigenetics-related molecule inhibitors, protein post-translational modification inhibitors, and other antitumor agents. Specific examples of "concomitant drugs" include azacitidine, vorinostat, decitabine, romidepsin, idarubicin, daunorubicin, doxorubicin, enocitabine, cytarabine, mitoxantrone, thioguanine, etoposide, ifosfamide, cyclophosphamide, dacarbazine, temozolomide, nimustine, busulfan, procarbazine, melphalan, ranimustine, all-trans retinoic acid, tamibarotene, cisplatin, carboplatin, oxaliplatin, irinotecan, bleomycin, mitomycin C, methotrexate, paclitaxel, docetaxel, gemcitabine, tamoxifen, thiotepa, tegafur, fluorouracil, and everolim. serotoninib, temsirolimus, gefitinib, erlotinib, imatinib, crizotinib, osimertinib, afatinib, dasatinib, bosutinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, lapatinib, nilotinib, ibrutinib, ceritinib, alectinib, tofacitinib, baricitinib, ruxolitinib, and ora These include parib, sorafenib, vemurafenib, dabrafenib, trametinib, palbociclib, bortezomib, carfilzomib, rituximab, cetuximab, trastuzumab, bevacizumab, panitumumab, nivolumab, atezolizumab, mogamulizumab, alemtuzumab, ofatumumab, ipilimumab, ramucirumab, brentuximab vedotin, gemtuzumab ozogamicin, and inotuzumab ozogamicin.
[0115] The timing of administration of the drug of the present disclosure and the concomitant drug is not limited, and they may be administered to the subject simultaneously or at appropriate intervals. The drug of the present disclosure and the concomitant drug may be administered as a combined preparation, or the concomitant drug may be administered as a separate formulation from the drug of the present disclosure, or may be administered via a different administration route. The dosage of the concomitant drug can be appropriately selected based on clinically used doses. The compounding ratio of the drug of the present disclosure and the concomitant drug can be appropriately selected depending on the subject, administration route, target disease, symptoms, combination, etc.
[0116] The compound or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof may be administered orally or parenterally, with oral administration being preferred. The dosage varies depending on the administration method, the patient's symptoms, age, and other factors, but is typically in the range of 0.01 to 30 mg / kg / day, preferably 0.05 to 20 mg / kg / day, and more preferably 0.1 to 10 mg / kg / day. Another preferred dosage range is typically 0.01 mg to 1600 mg / day, preferably 0.1 mg to 1200 mg / day, more preferably 0.5 mg to 1000 mg / day, even more preferably 1 mg to 800 mg / day, and most preferably 5 mg to 600 mg / day. The compound may be administered once or several times a day, for example, one, two, or three doses per administration.
[0117] Examples of the present disclosure are given below, but these examples are provided to illustrate the present disclosure and do not limit the present disclosure in any way. Furthermore, the present disclosure may be modified within the scope of the present disclosure. The names of compounds shown in the following examples, test examples, and comparative examples do not necessarily conform to the IUPAC nomenclature.
[0118] In the present Examples, Test Examples and Comparative Examples, unless otherwise specified, % in the solution indicates (wt %), and % in the particles indicates % by weight.
[0119] Unless otherwise specified, the additives used in the present Examples, Test Examples, and Comparative Examples were as follows: Hydroxypropyl cellulose (HPC-L (6-10 mPa·s 注1)) ): Nippon Soda Co., Ltd. Polyvinyl alcohol (Gohsenol) TM EG-05P (4.5-6.1mm 2 / s 注2) ) Hypromellose (TC-5 TM R (6 mPa·s 注1) ) ): Shin-Etsu Chemical Co., Ltd. Partially pregelatinized starch (PCS) TM PC-10): Asahi Kasei Chemical Corporation Croscarmellose sodium (Ac-Di-Sol TM DuPont Crospovidone (Kollidon) TM CL): BASF sodium starch glycolate (Primojel) TM ): DFE Pharma Mannitol (PEARLITOL 50C): Roquette Sodium stearyl fumarate (PRUV TM ): JRS PHARMA GmbH & Co. KG Carnauba wax (Polishing Wax 105): Nippon Wax Co., Ltd. Yellow ferric oxide S: Kishi Chemical Co., Ltd. Iron oxide S: Kishi Chemical Co., Ltd. Note that OPADRY used in this example is a film coating agent that does not affect dissolution. Note 1) Manufacturer's catalog value for a 2% solution at 20°C. Note 2) Manufacturer's catalog value for a 4% solution at 20°C.
[0120] Example 1: Tablets containing the tartrate salt of the present compound (1) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 1-1 were produced.
[0121] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (1) 2850 g of purified water was placed in an SUS beaker, and 150 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare 5 wt% hydroxypropyl cellulose solution (1).
[0122] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts shown in Table 1-2 and the production conditions shown in Table 1-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts shown in Table 1-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (1) in the charge amount shown in Table 1-2 was sprayed onto the mixture while fluidizing. After that, the mixture was dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0123] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 1-4. Granules containing the tartrate of the present compound in the amount shown in Table 1-4 were placed in a plastic bag, followed by addition of sodium stearyl fumarate in the amount shown in Table 1-4, and the bag was mixed (50 rotations vertically and 50 rotations horizontally, a total of 100 rotations).
[0124] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 1-5 so that each tablet contained 50 mg of the tartrate salt of the present compound.
[0125] (5) Preparation of Film Coating Solution (1) 540.0 g of purified water was placed in a stainless steel tank, and 60.0 g of a coating component mixture consisting of hypromellose, titanium oxide, propylene glycol, yellow ferric oxide, and ferric oxide was gradually added with stirring to disperse and dissolve the mixture. This liquid was passed through a 108 μm mesh screen to prepare Film Coating Solution (1).
[0126] (6) Production of Film-Coated Tablets Containing the Tartrate of the Present Compound Film-coated tablets containing the tartrate of the present compound were produced under the conditions described in Table 1-6. First, 231.16 g of plain tablets were placed in a coating machine (HC-LABO model, manufactured by Freund Corporation), and the coating pan was heated under the conditions described in Table 1-6 until the exhaust temperature reached 45°C while rotating. Next, while rotating the coating pan at 20 rpm, film coating solution (1) was sprayed under the conditions described in Table 1-6, and film coating was performed until the coating amount reached approximately 3.8 mg. Thereafter, the coating pan was rotated at 12 rpm and dried until the exhaust temperature reached 50°C. After removing the tablets, polishing wax 105 was added, followed by bag mixing and polishing.
[0127] Example 2: Tablets containing the tartrate salt of the present compound (2) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 2-1 were produced.
[0128] B. Manufacturing Method (1) Preparation of 5 wt% Hydroxypropylcellulose Solution (2) 1900 g of purified water was placed in an SUS beaker, and 100 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropylcellulose solution (2).
[0129] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts shown in Table 2-2 and the production conditions shown in Table 2-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts shown in Table 2-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5.5 wt% hydroxypropyl cellulose solution (2) in the charge amount shown in Table 2-2 was sprayed while fluidizing. Thereafter, the mixture was dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0130] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 2-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 2-4 were placed in a plastic bag, followed by addition of sodium stearyl fumarate in the amount shown in Table 2-4, and the bag was mixed (50 rotations vertically and 50 rotations horizontally, a total of 100 rotations).
[0131] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 2-5 so that each tablet contained 50 mg of the tartrate salt of the present compound.
[0132] Example 3: Tablets containing the tartrate salt of the present compound (3) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 3-1 were produced.
[0133] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (3) 2850 g of purified water was placed in an SUS beaker, and 150 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (3).
[0134] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts shown in Table 3-2 and the production conditions shown in Table 3-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts shown in Table 3-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (3) in the charge amount shown in Table 3-2 was sprayed while fluidizing. Thereafter, the mixture was dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0135] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 3-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 3-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 3-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0136] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tablet press (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 3-5 so that each tablet contained 25 mg of the tartrate salt of the present compound.
[0137] (5) Preparation of Film Coating Solution (2) 1,800.00 g of purified water was weighed. 0.32 g of yellow ferric oxide and 0.16 g of ferric oxide were added to a portion of the purified water and dispersed using a Robomics (T.K. Homomixer MARK2.5). 199.52 g of a coating component mixture consisting of hypromellose, titanium oxide, and propylene glycol was gradually added to a portion of the purified water while stirring, and dispersed and dissolved. A solution in which a pigment had been dispersed was added to this solution. Finally, this solution was passed through a 108 μm mesh screen to obtain film coating solution (2).
[0138] (6) Production of Film-Coated Tablets Containing the Tartrate of the Present Compound Film-coated tablets containing the tartrate of the present compound were produced under the conditions described in Table 3-6. First, 400.00 g of plain tablets were placed in a coating machine (HC-LABO model, manufactured by Freund Corporation), and the coating pan was heated under the conditions described in Table 3-6 until the exhaust temperature reached 45°C while rotating. Next, while rotating the coating pan at 20 rpm, film coating solution (2) was sprayed under the conditions described in Table 3-6, and film coating was performed until the coating amount reached approximately 2.4 mg. Thereafter, the coating pan was rotated at 12 rpm and dried until the exhaust temperature reached 50°C. After removing the tablets, polishing wax 105 was added, followed by bag mixing and polishing.
[0139] Example 4: Tablets containing the tartrate salt of the present compound (4) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 4-1 were produced.
[0140] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (4) 2850 g of purified water was placed in an SUS beaker, and 150 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (4).
[0141] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts shown in Table 4-2 and the production conditions shown in Table 4-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts shown in Table 4-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (4) in the charge amount shown in Table 4-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0142] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 4-4. Granules containing the tartrate of the present compound in the amount shown in Table 4-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 4-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0143] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 4-5 so that each tablet contained 50 mg of the tartrate salt of the present compound.
[0144] (5) Preparation of Film Coating Solution (3) 900.00 g of purified water was weighed. 0.24 g of yellow ferric oxide was added to a portion of the purified water and dispersed using a Robomics (T.K. Homomixer MARK2.5). 99.76 g of a coating component mixture consisting of hypromellose, titanium oxide, and propylene glycol was gradually added to a portion of the purified water while stirring, and dispersed and dissolved. A solution in which a pigment had been dispersed was added to this solution. Finally, this solution was passed through a screen with a mesh size of 108 μm to obtain film coating solution (3).
[0145] (6) Production of film-coated tablets containing the tartrate salt of the present compound Film-coated tablets containing the tartrate salt of the present compound were produced under the conditions described in Table 4-6. First, 367.43 g of plain tablets were placed in a coating machine (HC-LABO model, manufactured by Freund Corporation), and the coating pan was heated under the conditions described in Table 4-6 until the exhaust temperature reached 45 ° C. while rotating. Next, while rotating the coating pan at 20 rpm, film coating solution (3) was sprayed under the conditions described in Table 4-6, and film coating was performed until the coating amount reached approximately 3.8 mg. Thereafter, the coating pan was rotated at 12 rpm and dried until the exhaust temperature reached 50 ° C. After removing the tablets, polishing wax 105 was added, followed by bag mixing and polishing.
[0146] Example 5: Tablets containing the tartrate salt of the present compound (5) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 5-1 were produced.
[0147] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (5) 2850 g of purified water was placed in an SUS beaker, and 150 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (5).
[0148] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 5-2 and the production conditions listed in Table 5-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 5-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (5) in the charge amount listed in Table 5-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0149] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 5-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 5-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 5-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0150] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tablet press (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 5-5 so that each tablet contained 125 mg of the tartrate salt of the present compound.
[0151] (5) Preparation of Film Coating Solution (4) 900.00 g of purified water was weighed. 0.24 g of ferric oxide was added to a portion of the purified water and dispersed using a Robomics (T.K. Homomixer MARK2.5). 99.76 g of a coating component mixture consisting of hypromellose, titanium oxide, and propylene glycol was gradually added to a portion of the purified water while stirring, and dispersed and dissolved. A solution in which a pigment had been dispersed was added to this solution. Finally, this solution was passed through a screen with a mesh size of 108 μm to obtain film coating solution (4).
[0152] (6) Production of Film-Coated Tablets Containing the Tartrate of the Present Compound Film-coated tablets containing the tartrate of the present compound were produced under the conditions described in Table 5-6. First, 366.80 g of plain tablets were placed in a coating machine (HC-LABO model, manufactured by Freund Corporation), and the coating pan was heated under the conditions described in Table 5-6 until the exhaust temperature reached 45 ° C. while rotating. Next, while rotating the coating pan at 20 rpm, film coating solution (4) was sprayed under the conditions described in Table 1-6, and film coating was performed until the coating amount reached approximately 6.0 mg. Thereafter, the coating pan was rotated at 12 rpm and dried until the exhaust temperature reached 50 ° C. After removing the tablets, polishing wax 105 was added, followed by bag mixing and polishing.
[0153] Example 6: Tablets containing the tartrate salt of the present compound (6) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 6-1 were produced.
[0154] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (6) 2850 g of purified water was placed in an SUS beaker, and 150 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (6).
[0155] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 6-2 and the production conditions listed in Table 6-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 6-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (6) in the charge amount listed in Table 6-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0156] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 6-4. Granules containing the tartrate of the present compound in the amount shown in Table 6-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 6-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0157] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tablet press (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 6-5 so that each tablet contained 50 mg of the tartrate salt of the present compound.
[0158] Example 7: Tablets containing the tartrate salt of the present compound (7) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 7-1 were produced.
[0159] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (7) 2850 g of purified water was placed in an SUS beaker, and 150 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (7).
[0160] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 7-2 and the production conditions listed in Table 7-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 7-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (7) in the charge amount listed in Table 7-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0161] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 7-4. Granules containing the tartrate of the present compound in the amount shown in Table 7-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 7-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0162] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tablet press (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 7-5 so that each tablet contained 50 mg of the tartrate salt of the present compound.
[0163] Example 8: Tablets containing the tartrate salt of the present compound (8) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 8-1 were produced.
[0164] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (8) 2850 g of purified water was placed in an SUS beaker, and 150 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (8).
[0165] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 8-2 and the production conditions listed in Table 8-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 8-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (8) in the charge amount listed in Table 8-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0166] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 8-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 8-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 8-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0167] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 8-5 so that each tablet contained 25 mg of the tartrate salt of the present compound.
[0168] (5) Preparation of Film Coating Solution (5) 1,800.00 g of purified water was weighed. 0.32 g of yellow ferric oxide and 0.16 g of ferric oxide were added to a portion of the purified water and dispersed using a Robomics (T.K. Homomixer MARK2.5). 199.52 g of a coating component mixture consisting of hypromellose, titanium oxide, and propylene glycol was gradually added to a portion of the purified water while stirring, and dispersed and dissolved. A solution in which a pigment had been dispersed was added to this solution. Finally, this solution was passed through a 108 μm mesh screen to obtain film coating solution (5).
[0169] (6) Production of film-coated tablets containing the tartrate salt of the present compound Film-coated tablets containing the tartrate salt of the present compound were produced under the conditions described in Table 8-6. First, 400.06 g of plain tablets were placed in a coating machine (HC-LABO model, manufactured by Freund Corporation), and the coating pan was heated under the conditions described in Table 8-6 until the exhaust temperature reached 45 ° C. while rotating. Next, while rotating the coating pan at 20 rpm, the film coating solution (5) was sprayed under the conditions described in Table 8-6, and film-coated until the coating amount reached approximately 2.4 mg. Thereafter, the coating pan was rotated at 12 rpm and dried until the exhaust temperature reached 50 ° C. After removing the tablets, polishing wax 105 was added, followed by bag mixing and polishing.
[0170] Example 9: Tablets containing the tartrate salt of the present compound (9) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 9-1 were produced.
[0171] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (9) 3,325 g of purified water was placed in an SUS beaker, and 175 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (9).
[0172] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts shown in Table 9-2 and the production conditions shown in Table 9-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts shown in Table 9-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (9) in the charge amount shown in Table 9-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0173] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 9-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 9-4 were placed in a plastic bag, followed by addition of sodium stearyl fumarate in the amount shown in Table 9-4, and the bag was mixed (50 rotations vertically and 50 rotations horizontally, a total of 100 rotations).
[0174] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tablet press (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 9-5 so that each tablet contained 125 mg of the tartrate salt of the present compound.
[0175] Example 10: Tablets containing the tartrate salt of the present compound (10) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 10-1 were produced.
[0176] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (10) 24,624 g of purified water was placed in an SUS beaker, and 1,296 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (10).
[0177] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 10-2 and the production conditions listed in Table 10-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 10-2 were charged into a fluidized bed granulation dryer (manufactured by Freund Corporation, NFLF-30SJC model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (10) in the charge amount listed in Table 10-2 was sprayed onto the mixture while fluidizing. After that, the mixture was dried while fluidizing until the exhaust temperature reached 45°C and then removed from the vessel. The removed granules were then passed through a Comil for dry sieving to obtain granules containing the tartrate of the present compound.
[0178] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 10-4. Granules containing the tartrate of the present compound in the amount shown in Table 10-4 were charged into a 110 L hopper bottle, followed by addition of sodium stearyl fumarate in the amount shown in Table 10-4, and mixing was carried out at 20 rpm for 15 minutes using a mixer (manufactured by Yamazaki Metal Industry Co., Ltd., MB02-001 model).
[0179] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (Kikusui Seisakusho, AQUARIUS3-A type) under the conditions shown in Table 10-5 so that each tablet contained 125 mg of the tartrate salt of the present compound.
[0180] (5) Preparation of Film Coating Solution (6) 10,800 g of purified water was weighed. 9.6 g of yellow ferric oxide and 4.8 g of ferric oxide were added to a portion of the purified water and dispersed using a Robomics (T.K. Homojietter Type O, Homomixer MARK II 40). 1,185.6 g of a coating component mixture consisting of hypromellose, titanium oxide, and propylene glycol was gradually added to a portion of the purified water while stirring, and dispersed and dissolved. To this solution was added a solution in which a pigment had been dispersed. Finally, this solution was passed through a screen with a mesh size of 108 μm to obtain film coating solution (6).
[0181] (6) Production of Film-Coated Tablets Containing the Tartrate of the Present Compound Film-coated tablets containing the tartrate of the present compound were produced under the conditions described in Table 10-6. The plain tablets to be used for film coating were placed in a coating machine (Freund Corporation, Model AQC-80), and while gradually rotating the coating pan, they were heated under the conditions described in Table 10-6 until the exhaust temperature reached 50°C. Next, while rotating the coating pan at 10 rpm, the film coating solution (6) was sprayed under the conditions described in Table 10-6, and film-coated until the coating amount reached approximately 7.5 mg. Thereafter, the coating pan was dried while rotating intermittently at 4.0 rpm until the exhaust temperature reached 60°C. After drying, polishing wax 105 was added to the tablets to produce film-coated tablets.
[0182] Example 11: Tablets containing the tartrate salt of the present compound (11) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 11-1 were produced.
[0183] B. Manufacturing Method (1) Preparation of 5 wt% Polyvinyl Alcohol Solution (1) Approximately 500 g of purified water was placed in an SUS beaker, and 100 g of EG-05P was gradually added and dispersed. Approximately 1,500 g of purified water was heated to 80°C and added to the dispersed solution to dissolve. After standing overnight, the mixture was stirred again, and the weight was corrected for the evaporated purified water, to prepare a 5 wt% polyvinyl alcohol solution (1) of 2,000 g in total.
[0184] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts shown in Table 11-2 and the production conditions shown in Table 11-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts shown in Table 11-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% polyvinyl alcohol solution (1) in the charge amount shown in Table 11-2 was sprayed while fluidizing. Thereafter, the mixture was dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0185] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 11-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 11-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 11-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0186] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 11-5 so that each tablet contained 25 mg of the tartrate salt of the present compound.
[0187] Example 12: Tablets containing the tartrate salt of the present compound (12) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 12-1 were produced.
[0188] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (11) 2375 g of purified water was placed in an SUS beaker, and 125 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (11).
[0189] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 12-2 and the production conditions listed in Table 12-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and crospovidone in the charge amounts listed in Table 12-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (11) in the charge amount listed in Table 12-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0190] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 12-4. Granules containing the tartrate of the present compound in the amount shown in Table 12-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 12-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0191] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 12-5 so that each tablet contained 25 mg of the tartrate salt of the present compound.
[0192] Example 13: Tablets containing the tartrate salt of the present compound (13) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 13-1 were produced.
[0193] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (12) 2375 g of purified water was placed in an SUS beaker, and 125 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (12).
[0194] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 13-2 and the production conditions listed in Table 13-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and sodium starch glycolate in the charge amounts listed in Table 13-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (12) in the charge amount listed in Table 13-2 was sprayed while fluidizing. Thereafter, the mixture was dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0195] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 13-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 13-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 13-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0196] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tablet press (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 13-5 so that each tablet contained 25 mg of the tartrate salt of the present compound.
[0197] Example 14: Tablets containing the tartrate salt of the present compound (14) In this example, the following partially pregelatinized starch was used: STARCH 1500 TM : Colorcon A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 14-1 were produced.
[0198] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (13) 2375 g of purified water was placed in an SUS beaker, and 125 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (13).
[0199] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 14-2 and the production conditions listed in Table 14-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 14-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (13) in the charge amount listed in Table 14-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0200] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 14-4. Granulated granules containing the tartrate of the present compound in the amount shown in Table 14-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 14-4, and mixing was carried out for 10 minutes at 40 rpm using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0201] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 14-5 so that each tablet contained 25 mg of the tartrate salt of the present compound.
[0202] Comparative Example 1: Tablets containing the tartrate salt of the present compound (15) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 15-1 were produced.
[0203] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (14) 684 g of purified water was placed in an SUS beaker, and 36 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (14).
[0204] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 15-2 and the production conditions listed in Table 15-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 15-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (14) in the charge amount listed in Table 15-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0205] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 15-4. Granules containing the tartrate of the present compound in the amount shown in Table 15-4 were placed in a plastic bag, followed by addition of sodium stearyl fumarate in the amount shown in Table 15-4, and the bag was mixed (50 rotations vertically and 50 rotations horizontally, a total of 100 rotations).
[0206] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 15-5 so that each tablet contained 50 mg of the tartrate salt of the present compound.
[0207] Comparative Example 2: Tablets containing the tartrate salt of the present compound (16) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 16-1 were produced.
[0208] B. Production method (1) Preparation of 5 wt% hydroxypropyl cellulose solution (15) 684 g of purified water was placed in an SUS beaker, and 36 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hydroxypropyl cellulose solution (15).
[0209] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 16-2 and the production conditions listed in Table 16-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 16-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hydroxypropyl cellulose solution (15) in the charge amount listed in Table 16-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0210] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 16-4. Granules containing the tartrate of the present compound in the amount shown in Table 16-4 were placed in a plastic bag, followed by addition of magnesium stearate in the amount shown in Table 16-4, and the bag was mixed (50 rotations vertically and 50 rotations horizontally, a total of 100 rotations).
[0211] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 16-5 so that each tablet contained 50 mg of the tartrate salt of the present compound.
[0212] Comparative Example 3: Tablets containing the tartrate salt of the present compound (17) A. Formulation of uncoated tablets containing the tartrate salt of the present compound Granulated granules, mixed powders and uncoated tablets having the compositions shown in Table 17-1 were produced.
[0213] B. Production method (1) Preparation of 5 wt% hypromellose solution (1) 1900 g of purified water was placed in an SUS beaker, and 100 g of HPC-L was gradually added with stirring to dissolve. After standing overnight, the mixture was stirred again to prepare a 5 wt% hypromellose solution (1).
[0214] (2) Production of Granulated Granules Containing the Tartrate of the Present Compound Granulated granules containing the tartrate of the present compound were produced using the charge amounts listed in Table 17-2 and the production conditions listed in Table 17-3. First, the tartrate of the present compound, D-mannitol, partially pregelatinized starch, and croscarmellose sodium in the charge amounts listed in Table 17-2 were charged into a fluidized bed granulation dryer (Powrex Corporation, Multiplex MP-01 model) and mixed while fluidizing until the exhaust temperature reached 40°C. Next, a 5 wt% hypromellose solution (1) in the charge amount listed in Table 17-2 was sprayed onto the mixture while fluidizing. The mixture was then dried while fluidizing until the exhaust temperature reached 45°C, and then removed from the vessel. The removed granules were passed through a sieve with a mesh size of 710 μm to obtain granulated granules containing the tartrate of the present compound.
[0215] (3) Production of Mixed Powder Containing Tartrate of the Present Compound Mixed powder containing the tartrate of the present compound was produced in the amount shown in Table 17-4. Granules containing the tartrate of the present compound in the amount shown in Table 17-4 were charged into a 10 L V-shaped container, followed by addition of sodium stearyl fumarate in the amount shown in Table 17-4, and mixing was carried out at 40 rpm for 10 minutes using a mixer (Tsutsui Scientific Instruments Co., Ltd., S-5 model).
[0216] (4) Production of uncoated tablets containing the tartrate salt of the present compound Uncoated tablets were produced using a rotary tableting machine (VELC, manufactured by Kikusui Seisakusho) under the conditions shown in Table 17-5 so that each tablet contained 25 mg of the tartrate salt of the present compound.
[0217] The quality of the formulations obtained by the above-mentioned methods was evaluated by the following methods. Test Example 1: Evaluation of tableting properties and measurement of uncoated tablet shape, hardness, and friability For Examples 1 to 14 and Comparative Examples 1 and 2, tableting properties were evaluated, and the thickness, hardness, and friability of the uncoated tablets were measured. The thickness of the uncoated tablets was measured using a special Digimatic Thickness Gauge 547-301, and the hardness was measured using a tablet breaking strength tester TH-203MP manufactured by Toyama Sangyo Co., Ltd., and the average value of 5 or 10 tablets was recorded. In addition, tablet friability tests were performed using a FRIABILATOR TFT-1200 manufactured by Toyama Sangyo Co., Ltd., in accordance with the test method described in the Japanese Pharmacopoeia. The measurement results are shown in Table 18. As shown in Table 18, Examples 1 to 14 exhibited good tableting properties, hardness, and friability. In Comparative Example 1, which contained 2% binder and 2% lubricant, sticking occurred, tableting properties were poor, and the hardness of the uncoated tablets was also low. In Comparative Example 2, which used 1% magnesium stearate as a lubricant, sticking occurred and die friction was observed, resulting in a further decrease in hardness compared to Comparative Example 1, making continuous tableting difficult. It was revealed that by using 4% or more binder and 2% or more lubricant, tablets showing significantly excellent tableting properties and high hardness can be produced.
[0218] Test Example 2: Dissolution Test For Examples 1 to 14 and Comparative Example 3, dissolution tests were conducted according to the Japanese Pharmacopoeia General Test Dissolution Test Method under the following conditions. <Dissolution Test Conditions> Method: Dissolution Test Method (Paddle Method) of the Japanese Pharmacopoeia General Test Method Rotation Speed: 50 rpm Test Solution Volume: 900 mL Test Solution Temperature: 37°C ± 0.5°C Test Solution: 0.1 N HCl <Sample Solution Preparation> A tablet was placed in a test vessel containing 900 mL of test solution. 5, 10, and 15 minutes after the start of the test, 10 mL of test solution was collected using a 10 mL syringe and slowly filtered through a membrane filter with a pore size of 0.45 μm or less. At least 2 mL of the initial filtrate was removed, and this was used as the sample solution. <Standard Solution Preparation> 50.00 mg of the tartrate salt of this compound was weighed into a 300 mL volumetric flask and dissolved in the dissolution test solution. Further, this solution was weighed to 10 mL in a 30 mL volumetric flask and dissolved in the dissolution test solution. This was used as the mother solution for the standard solution. Each sample was diluted with this mother solution according to its volume, and the diluted solution was used as the sample for the standard solution. <High-Performance Liquid Chromatography Analysis Condition 1> Analysis Condition 1 was used in the tests of Examples 1 and 2. High-Performance Liquid Chromatography Apparatus: UFLC-XR manufactured by Shimadzu Corporation Detection wavelength: 260 nm Column: Xselect CSH C18 manufactured by Waters, 150 mm x 4.6 mm I.D. particle size 3.5 μm Mobile phase: water / methanol / perchloric acid mixture (1000 / 1000 / 1) Analysis time: 5 minutes Flow rate: 0.8 mL / min Column temperature: 40°C Injection amount: 5 μL Sample cooler temperature: 5°C Syringe cleaning solution: methanol / water mixture (1 / 1) <High-Performance Liquid Chromatography Analysis Condition 2> Analysis condition 2 was used in the tests of Examples 3 to 14 and Comparative Example 3. High-performance liquid chromatography Apparatus: Shimadzu UFLC-XR Detection wavelength: 260 nm Column: Waters Xselect CSH C18 150 mm x 4.6 mm I.D. Particle size 3.5 μm Mobile phase: Water / methanol / perchloric acid mixture (1000 / 1000 / 3) Analysis time: 5 minutes Flow rate: 0.8 mL / min Column temperature: 40°C Injection volume: 5 μL Sample cooler temperature: 25°C Syringe cleaning solution: Methanol / water mixture (1 / 1)
[0219] The results of the dissolution test are shown in Table 19. As shown in Table 19, the uncoated tablets and FC tablets of the present invention rapidly dissolve, and are expected to have high in vivo absorption. Furthermore, although there was a slight difference in the initial dissolution rate between the presence and absence of film coating, there was almost no difference in the dissolution rate at 15 minutes, and dissolution was not affected. Despite the use of relatively large amounts of binder and lubricant, tablets were produced that rapidly dissolve and exhibit good dissolution properties.
[0220] Test Example 3: Storage stability test (purity test) The conditions of the thermo-hygrostat were set to 40°C / 75% RH or 50°C / 85% RH, and the plain tablets prepared in Examples 1 to 14 were placed in HDPE bottles or brown screw-cap test tubes (material: glass) and stored in the thermo-hygrostat in an opened state for a predetermined period of time, after which a purity test was performed and the amount of related substances was evaluated. Test Condition 1 Test Condition 1 was used in the tests of Examples 1 and 2. Detector: Ultraviolet absorption spectrophotometer (measurement wavelength 220 nm) Column: Waters, Xselect CSH C18 150 mm x 4.6 mm ID particle size 3.5 μm Column temperature: Constant temperature around 40°C Mobile phase A: Water / perchloric acid mixture (10,000:1) Mobile phase B: Methanol Elution method: Gradient method Flow rate: 0.8 mL / min Area measurement range: 50 minutes after injection Sample cooler temperature: 5°C Dissolution solvent: Water / methanol / perchloric acid mixture (1,000 / 1,000 / 1) Syringe cleaning solution: Methanol / water mixture (1 / 1) Test condition 2 Test condition 2 was used in the tests of Examples 3 to 14. Detector: Ultraviolet absorption photometer (measurement wavelength 220 nm) Column: Waters, Xselect CSH C18 150 mm x 4.6 mm I.D. particle size 3.5 μm Column temperature: Constant temperature around 40°C Mobile phase A: Water / perchloric acid mixture (10,000:1) Mobile phase B: Methanol Elution method: Gradient method Flow rate: 0.8 mL / min Area measurement range: 60 minutes after injection Sample cooler temperature: 25°C Dissolution solvent: Water / methanol / perchloric acid mixture (1,000 / 1,000 / 3) Syringe cleaning solution: Methanol / water mixture (1 / 1)
[0221] The amount of related substances relative to this compound was calculated based on the peak area values obtained by liquid chromatography. The total amount of detected related substances is shown in Tables 20-1 and 20-2. As shown in Tables 20-1 and 20-2, the uncoated tablets of the present invention showed no increase in related substances even during the storage stability test, and exhibited good storage stability.
[0222] Test Example 4: Storage stability test (dissolution test) The conditions of the thermo-hygrostat were set to 40°C / 75% RH, and the plain tablets or FC tablets prepared in Examples 1 to 14 were placed in HDPE bottles and stored in the thermo-hygrostat in an opened state for a predetermined period of time. After that, a dissolution test was carried out under the conditions described in Test Example 2 in accordance with the Japanese Pharmacopoeia, General Test Method, Dissolution Test Method.
[0223] The results of the dissolution test are shown in Tables 21-1 and 21-2. As shown in Tables 21-1 and 21-2, the uncoated tablets and FC tablets of the present invention rapidly dissolve, and are expected to have high in vivo absorption. Furthermore, although there was a slight difference in the initial dissolution rate between the presence and absence of film coating, there was almost no difference in the dissolution rate at 15 minutes, and dissolution was not affected. Despite the use of relatively large amounts of binder and lubricant, tablets were produced that rapidly dissolve and exhibit good dissolution properties.
[0224] From the above results, it was revealed that the formulation of the present disclosure has good dissolution properties and storage stability, and furthermore, when provided as a tablet, suppresses tableting problems. As described above, the present disclosure has been illustrated using preferred embodiments, but it is understood that the scope of the present disclosure should be interpreted only by the claims. It is understood that the patents, patent applications, and other documents cited in this specification are incorporated by reference in their entirety as if the contents themselves were specifically set forth herein.
[0225] According to the present disclosure, it is possible to provide an oral solid preparation which contains, as an active ingredient, (i) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and which contains high contents of (ii) a binder and (iii) a lubricant, and which is inhibited from causing tableting trouble and has excellent dissolution properties.
Claims
1. An oral solid preparation containing: (1) 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharma- ceutically acceptable salt thereof, or a hydrate or solvate thereof; (2) 4.0 to 6.0% by weight of a binder based on 100% by weight of the preparation; and (3) 2.0 to 10.0% by weight of a lubricant based on 100% by weight of the preparation.
2. The oral solid formulation according to claim 1, wherein the content of the binder is 5.0 to 6.0% by weight based on 100% by weight of the formulation.
3. The oral solid formulation according to claim 1 or 2, wherein the binder is a water-soluble polymeric binder.
4. The oral solid formulation of claim 3, wherein the water-soluble polymeric binder is hydroxypropyl cellulose or polyvinyl alcohol.
5. The oral solid dosage form of claim 3, wherein the water-soluble polymeric binder is hydroxypropyl cellulose.
6. The oral solid formulation according to any one of claims 1 to 5, wherein the content of the lubricant is 2.0 to 6.0% by weight based on 100% by weight of the formulation.
7. The oral solid formulation according to any one of claims 1 to 5, wherein the content of the lubricant is 4.0 to 6.0% by weight based on 100% by weight of the formulation.
8. The oral solid formulation according to any one of claims 1 to 7, wherein the lubricant is sodium stearyl fumarate.
9. The oral solid formulation according to any one of claims 1 to 8, further comprising an excipient.
10. The oral solid formulation of claim 9, wherein the excipient is a hydrophilic excipient.
11. The oral solid formulation according to claim 10, wherein the hydrophilic excipient is one or a mixture of two or more selected from sugar alcohols, pregelatinized starches, lactose hydrate, and microcrystalline cellulose.
12. The oral solid formulation according to claim 10, wherein the hydrophilic excipient is one or a mixture of two or more selected from sugar alcohols, pregelatinized starches, and microcrystalline cellulose.
13. The oral solid formulation according to claim 10, wherein the hydrophilic excipient is one or a mixture of two or more selected from sugar alcohols and pregelatinized starches.
14. The oral solid dosage form of claim 10, wherein the hydrophilic excipient is a mixture of sugar alcohols and pregelatinized starches.
15. The oral solid formulation according to any one of claims 11 to 14, wherein the pregelatinized starches are partially pregelatinized starches.
16. The oral solid formulation according to any one of claims 11 to 15, wherein the sugar alcohol is D-mannitol.
17. The oral solid formulation according to any one of claims 1 to 16, further comprising a disintegrant.
18. The oral solid formulation according to claim 17, wherein the content of the disintegrant is 0.5 to 50.0% by weight based on 100% by weight of the formulation.
19. The oral solid formulation according to claim 17, wherein the content of the disintegrant is 0.5 to 30.0% by weight based on 100% by weight of the formulation.
20. The oral solid formulation according to claim 17, wherein the content of the disintegrant is 0.5 to 20.0% by weight based on 100% by weight of the formulation.
21. The oral solid formulation according to any one of claims 17 to 20, wherein the disintegrant is one or a mixture of two or more selected from croscarmellose sodium, sodium starch glycolate, and crospovidone.
22. The oral solid formulation according to any one of claims 17 to 20, wherein the disintegrant is one or a mixture of two or more selected from croscarmellose sodium and sodium starch glycolate.
23. The oral solid formulation according to any one of claims 17 to 20, wherein the disintegrant is croscarmellose sodium.
24. The oral solid formulation according to any one of claims 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharma- ceutically acceptable salt thereof, or a hydrate or solvate thereof is 0.5 to 70% by weight, relative to 100% by weight of the formulation.
25. The oral solid formulation according to any one of claims 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharma- ceutically acceptable salt thereof, or a hydrate or solvate thereof is 10 to 50% by weight, relative to 100% by weight of the formulation.
26. The oral solid formulation according to any one of claims 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharma- ceutically acceptable salt thereof, or a hydrate or solvate thereof is 15 to 40% by weight, relative to 100% by weight of the formulation.
27. The oral solid formulation according to any one of claims 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharma- ceutically acceptable salt thereof, or a hydrate or solvate thereof is 15 to 38% by weight relative to 100% by weight of the formulation.
28. The oral solid formulation according to any one of claims 1 to 23, wherein the content of the 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide or a pharma- ceutically acceptable salt thereof, or a hydrate or solvate thereof is 20 to 38% by weight relative to 100% by weight of the formulation.
29. The oral solid formulation according to any one of claims 1 to 28, which is produced using a fluidized bed granulation method.
30. The oral solid formulation according to any one of claims 1 to 29, which is film-coated with a coating agent.
31. An oral solid formulation according to any one of claims 1 to 30 for treating and / or preventing tumors.
